The establishment of the new treatment strategy according to angiogenetic dependence using a bladder cancer carcinogenic model

• Project/Area Number: 23791789
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Keio University
• Principal Investigator: HAGIWARA Masayuki 慶應義塾大学, 医学部・泌尿器科, 助教 (70464922)
• Project Period (FY): 2011 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
• Keywords: 腫瘍学 / 膀胱癌 / マウス膀胱癌同所性発癌モデル / ARB

Research Abstract

The cancerogenesis of the bladder cancer was accelerated by ARB(Irbesartan, Telmisartan, Candesartan) in a mouse bladder carcinogenic model using N-butyl-N-(4-hydroxybutyl) nitrosamine. Andcompared to ARB (Candesartan) having no PPAR-γ ac